United States: Animal Supplements Still In Limbo, Facing Increased FDA Scrutiny

The thousands of food, agriculture and life sciences companies regulated by the federal government already face a barrage of complicated regulations. Add in significant regulatory uncertainty and a major reorganization of the governing agency and you see the current predicament of the animal supplement industry.

In this post, we'll break down the current structure of the agencies governing the animal dietary supplement industry, detail the regulatory conflict between human and animal supplements, and offer some tips for animal supplement companies that will likely face increased FDA scrutiny and enforcement in the near future.

A major reshuffling

On January 13, 2013, the Federal Register published a Final Notice amending the Statement of Organization Functions and Delegations of Authority for the Department of Health and Human Services (HHS) on the reorganization within the FDA. This reorganization, approved prior to the publication in the Federal Register, brought the Center for Veterinary Medicine (CVM) under the Center for Food Safety and Applied Nutrition (CFSAN), thereby creating the new "Office of Foods and Veterinary Medicine" (OFVM). This reorganization happened in large part because of the mandates under the Food Safety and Modernization Act (FSMA) affecting both human and animal food chains. The goal in bringing these centers under one office was to hopefully create a more coordinated approach to the FDA's risk-based mandates related to the safety of the U.S. food chain.

On its face, this reorganization may make sense, provided that all of the issues the former CVM dealt with were related only to animals that are part of the human food chain (i.e., livestock). This is not the case, however, as the CVM was also charged with reviewing and approving animal drugs, dietary supplements, feed, and feed additives for animals defined as companion animals, such as dogs, cats and horses. This consolidation has caused the animal industry to wonder what impact the reorganization will have on its business, particularly for companies producing animal supplements. This lack of clarity for animal supplement manufacturers initially arose from an FDA statement related to the applicability of the Dietary Supplement Health and Education Act (DSHEA) and the nature of animal supplements themselves. Combined with the January 2013 reorganization of the Centers for Veterinary Medicines, the issue remains a major source of confusion and risk for industry members.

Human vs. animal supplements

Before DSHEA, human dietary supplements were inconsistently regulated as a food, a drug, or not regulated at all. These products were subject to inconsistent and seemingly random enforcement with varying requirements levied upon manufacturers based upon a case-by-case consideration of the product in question. Further, the animal supplement market was essentially unregulated. Companies were left with a market rife with confusion and varying product qualities and types. As a result, DSHEA was enacted to define dietary supplements as their own category of FDA-regulated products. These products would be regulated similarly to food. Thus, DSHEA added to the FDCA a definition for "dietary supplements" that states in relevant part:

  • The term "dietary supplement"—

    (1) means a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients...[redacted]

    Except for purposes of section 201(g), a dietary supplement shall be deemed to be a food within the meaning of this Act.

21 U.S.C. § 321(ff). (emphasis added). Simply, DSHEA defines dietary supplements as products which are treated like food products by the FDA. 

However, in 1996 and reiterated again in 2002, the FDA stated that DSHEA only applied to human dietary supplements and not animal supplements. The FDA went on to state that it was the position of the agency that animal supplements could and would be regulated as either a drug, food or feed additive. Specifically, the FDA stated that,

  • ...substances marketed as dietary supplements for humans still fall under the pre-DSHEA regulatory scheme when marketed for animals; that is, they are considered food, food additives, new animal drugs, or [Generally Recommended As Safe] depending on the intended use. Most of these types of products on the market would be considered unapproved and unsafe food additives or new drugs. The rationale behind this conclusion was the lack of language both surrounding DSHEA as well as the lack of language in DSHEA concerning animal supplements. Based on the lack of language, the FDA concluded that the Act was primarily concerned with improving the health of humans in the U.S. The FDA further stated that it was the agency's position that animal supplements could be regulated as an animal drug, a feed or a feed additive.

(61 FR § 17706.) Having made the pronouncement that DSHEA only applies to human supplements, the FDA has left a large market segment unregulated when the product does not fit within the applicable definitions of regulated products, specifically feed, feed additives or animal drugs:

  • Animal feed is defined as an article of food or animal consumption. 
  • A drug is defined as an article intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease.
  • A feed additive is typically any substance which is expected to become a component of animal food either as an ingredient or by top dressing a feed or placement in the animal's water.

A look at the animal supplement market reveals products similar to those products found in the human dietary supplement markets – products intended to affect or support a structure or function of the body. These products do not meet the definitions of a feed, feed additive or drug. Without the application of DSHEA, the result has been, to date, a virtually unregulated market. 

As a result, the FDA will regulate animal dietary supplements going forward in light of this consolidation and the ever increasing enforcement actions of the FDA with its authority under the Food Safety and Modernization Act (FSMA), enacted in 2011.

The FDA's enforcement stance

Many animal supplements do not in and of themselves provide nutrition. They are also not intended for use in the diagnosis, cure, or mitigation of disease, and they are not intended to become part of animal feed. Therefore, there remains a huge portion of the animal supplement product market that is relatively unregulated. To further complicate the issue for the animal health industry, the FDA has historically found animal dietary supplements to be "technically in violation of the law, [but] they are of low enforcement priority except for when public or animal health concerns arise." However, certain events may change that enforcement stance. One impetus for change is the Food Safety Modernization Act. It represents the first time in 70 years that the U.S. has directly addressed food safety and the security of the U.S. food supply. As a result of the FSMA, the FDA is now moving quickly to implement the FMSA requirements and increase its enforcement efforts over both human and animal products. Manufacturers can therefore expect increased scrutiny over their products.

Little guidance exists from the FDA for companies in the animal supplement industry, and compliance requirements remain difficult to pin down. Industry members must carefully analyze the market strategy for those products that have crossed over from the human dietary supplement market to the animal health market, a trend that is occurring with more and more frequency. These products may be the first to be subject to increased FDA scrutiny as they are already the subject of regulatory filings and therefore on the FDA's "radar." Regardless, a thorough analysis of an animal supplement is prudent prior to market entry. Carefully study the marketing and advertising claims surrounding those products, including product labeling and product testing in order to reduce the chances that the FDA takes notice of the product and decides to act.

What does this mean for animal dietary supplement products? Like so many other areas, it is highly likely that the FDA will find a jurisdictional basis, most likely within the FSMA or related food regulations to promulgate new rules to cover the void created by the current regulations and previous FDA statements. Further, companies will still have to ensure that labeling comports with applicable regulations. For example, the agency has allowed certain health claims to appear on animal food, provided that such claims generally meet the requirements set forth in the Nutrition Labeling Education Act (NLEA).

It generally takes time for the enforcement actions of the FDA to catch up to the new regulations; typically the industry is given time to reconcile its actions to those new regulations. Here the unique challenge will be understanding how to reconcile the animal supplement industry's compliance efforts in light of the current lack of clear FDA guidance and regulatory requirements. Moving forward, and until the FSMA and the recent FDA reorganization have had ample time to mature, animal supplement companies would be well served to ensure that their packaging, labeling and claims comport with the NLEA. Additionally, these companies should take care in the marketing and advertising of these products to avoid enforcement actions by the agency, as it is most likely that these products will find themselves being regulated as an unapproved drug.

At Thompson Coburn we have a team of attorneys with years of experience dealing with FDA regulations, including, but not limited to, product analysis and approvals, product labeling, seizures, FSMA compliance, New Animal Drug Applications, cGMPs and detention proceedings. We would be happy to speak to you and your company on how we can assist you with your FDA regulated products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions